Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2.5 µg, 10 µg, and 30 µg) of BI 1744 CL for 14 Days in Healthy Male and Female Volunteers (Double blind, Randomised, Placebo Controlled [at Each Dose Level] Study)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2.5 µg, 10 µg, and 30 µg) of BI 1744 CL for 14 Days in Healthy Male and Female Volunteers (Double blind, Randomised, Placebo Controlled [at Each Dose Level] Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2014

At a glance

  • Drugs Olodaterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top